Flagship Pioneering’s Post

Learn how #FlagshipFounded Abiologics is unlocking the next generation of biologics called Synteins™, a new biotherapeutic class with supranatural properties, revealing a world of new possibilities for patients. Jaclyn Dunphy and Mike Hamill explain how advances in generative protein design and optimization paired with automated chemical peptide synthesis are enabling this new approach to programmable biotherapeutics. Read more: https://bit.ly/4fy3sNf

To view or add a comment, sign in

Explore topics